
    
      The need exists to further assess the antibacterial agent azithromycin at differing doses in
      an HIV-infected population.

      Patients are randomized to receive azithromycin at 1 of 2 doses in a two-treatment,
      two-period, cross-over study. Dosing visits are separated by at least 14-day wash-out
      periods.
    
  